NewsRSS5 days ago
The author shares their personal experience undergoing an overnight sleep study, comparing it to a previous study from 2002. They describe feeling nervous about the procedure but acknowledge that despite being uncomfortable, the study was necessary for their health. The article appears to be a patient perspective piece about the importance of sleep studies for diagnosis.
WHY IT MATTERSSleep studies are often critical diagnostic tools for patients with rare diseases like SMA (spinal muscular atrophy) that can affect breathing and sleep quality, making this firsthand account relevant to others considering or preparing for the same procedure.
ResearchRSS5 days ago
Scientists found that haloperidol, a medication normally used to treat psychiatric conditions, may help treat spinal muscular atrophy (SMA) by increasing levels of a protein called SMN that is missing or low in SMA patients. In laboratory tests with mouse cells and human patient cells, haloperidol helped nerve cells survive longer, reduced harmful inflammation, and improved movement. This suggests haloperidol could potentially be used alongside or instead of current SMA treatments.
WHY IT MATTERSIf haloperidol proves effective in human trials, SMA patients could potentially benefit from a medication that already exists and is FDA-approved, potentially offering a faster path to treatment than developing entirely new drugs.
NewsRSS5 days ago
A patient shares their experience moving from pediatric (children's) doctors to adult healthcare providers. The article describes the mixed feelings of relief and worry that come with this major life transition, using a waiting room scene to explore how gratitude and fear can happen at the same time.
WHY IT MATTERSTransitioning from pediatric to adult care is a critical moment for patients with rare diseases like SMA, where continuity of specialized treatment and emotional support can directly affect health outcomes and quality of life.
NewsRSS5 days ago
This is a personal story about a family who discovered they were expecting an unplanned baby in spring 1997. The parents and their 10-year-old son had to adjust to the news of a new family member on the way. The article appears to be part of a larger story about how this unexpected event connected to a rare disease.
WHY IT MATTERSThis article is from SMA News Today, suggesting it relates to spinal muscular atrophy (SMA), but the excerpt provided does not contain specific medical information, treatment details, or actionable health guidance for SMA patients.
Clinical trialRSS5 days ago
AB Science is preparing to test an experimental drug called masitinib for ALS (a disease that affects nerve cells that control muscles). To protect their investment in this large clinical trial, the company bought special insurance that would reimburse them if the trial doesn't go as planned or costs more than expected.
WHY IT MATTERSThis insurance arrangement signals that AB Science is confident enough in masitinib to move forward with Phase 3 testing in ALS patients, which is a critical step toward potentially bringing a new treatment option to people living with this progressive disease.
ResearchRSS5 days ago
A study of 34 patients in Hong Kong found that Evrysdi (a medicine taken by mouth) helped children and adults with spinal muscular atrophy (SMA) move better and feel better in their daily lives. Patients who had never taken SMA medicine before saw the biggest improvements. The good results lasted for up to three years.
WHY IT MATTERSThis real-world evidence from Asian patients shows Evrysdi works well outside of clinical trials, which may help doctors decide if it's the right treatment for SMA patients in your region.
NewsRSS5 days ago
This article discusses how people living with SMA (spinal muscular atrophy) can maintain healthy friendships with their caregivers, even when conflicts arise. The author emphasizes the importance of their caregiver community and explores ways to resolve disagreements while keeping these important relationships strong.
WHY IT MATTERSPeople with SMA depend on caregivers for daily support, making it crucial to know how to address conflicts constructively without damaging relationships that are essential to their health and independence.
AdvocacyRSS5 days ago
Delphine Andrews, a life coach and disability advocate from North Carolina who lives with SMA (spinal muscular atrophy), shared her personal story in a podcast interview. She discussed how she learned to accept herself, help others with disabilities, and build a career as a life coach. The episode also covered important topics like managing caregivers and understanding how different parts of someone's identity intersect.
WHY IT MATTERSHearing from someone living with SMA about practical strategies for self-acceptance, caregiver management, and career transition can help newly diagnosed patients and families navigate similar challenges in their own lives.
ResearchRSS5 days ago
Researchers found that a simple electrical test using surface electrodes on the skin can measure nerve signals in people with spinal muscular atrophy (SMA). These signals were much weaker in SMA patients compared to healthy people, which suggests this test could be a useful way to track how the disease changes over time.
WHY IT MATTERSIf validated, this non-invasive surface electrode test could provide a faster, easier, and cheaper way to monitor SMA progression in clinical trials and patient care compared to current muscle strength assessments.
ResearchRSS5 days ago
A large study in the UK followed over 500,000 people for about 10 years and found that breathing polluted air for a long time does not appear to increase the risk of getting ALS, a disease that affects nerve cells that control muscles. Fewer than 1,000 people in the study developed ALS during the study period. This suggests that air pollution may not be an important risk factor for developing ALS.
WHY IT MATTERSIf you have ALS or are worried about developing it, this study suggests that long-term air pollution exposure is unlikely to be a major cause, which may help reduce anxiety about environmental risk factors you cannot easily control.
ResearchRSS5 days ago
Scientists discovered that some people with ALS (a disease that affects nerve cells controlling muscles) may develop the condition from new mutations that happen by chance in their nerve cells, rather than inheriting the mutation from their parents. This is different from inherited ALS cases where a parent passes down a faulty gene. This finding suggests there are multiple ways ALS can develop, which could help doctors better understand and treat the disease.
WHY IT MATTERSIf your ALS diagnosis is sporadic (not inherited), this research suggests your condition may have developed from random mutations in your nerve cells rather than a genetic predisposition, which could change how doctors approach your treatment and genetic counseling.
ResearchPUBMED5 days ago
Researchers in France studied a group of patients with myasthenia gravis (a rare disease where muscles become weak and tired easily) who were treated at special centers between 2007 and 2021. They collected information about these patients' backgrounds, how their disease developed, and how long they lived. This study helps doctors understand more about this disease and how to care for patients better.
WHY IT MATTERSThis registry data provides real-world evidence about myasthenia gravis outcomes and patient characteristics in France, which can help identify gaps in care and inform treatment guidelines for MG patients across Europe.
ResearchPUBMED6 days ago
Researchers in Germany studied health insurance records from 2017-2019 to understand how hemophilia A (a bleeding disorder) affects patients and how much it costs to treat. They found 257 patients with hemophilia A and grouped them by severity—mild, moderate, or severe—based on how much clotting medicine they needed. This study shows that insurance data can help doctors and researchers learn more about rare diseases like hemophilia A.
WHY IT MATTERSIf you have hemophilia A in Germany, this research demonstrates that your health insurance claims data can be used to better understand disease patterns, treatment costs, and care gaps—potentially leading to improved healthcare planning and resource allocation for your condition.
ResearchPUBMED6 days ago
Linear interstitial keratitis (LIK) is a very rare eye condition where a thin line of cloudiness forms in the clear part of the eye (the cornea). This study looked at 6 patients with this condition to better understand what it looks like, how doctors can diagnose it, and what treatments work best. The researchers found that the cloudy line usually appears near the edge of the cornea and can be seen clearly with special eye imaging tools.
WHY IT MATTERSThis is the largest study to date on linear interstitial keratitis, providing eye doctors with new guidance on diagnosis and treatment options for a condition that previously had no agreed-upon management approach.
Clinical trialCLINICALTRIALS6 days ago
Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.
WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. Fabry disease is a rare genetic condition where the body can't break down certain fatty substances, causing problems in the heart, kidneys, and nerves. If you need help paying for Fabry disease treatment, you'll need to check back later or explore other assistance programs.
WHY IT MATTERSIf you have Fabry disease and were counting on PAN Foundation's copay assistance or medication support, you'll need to find alternative financial resources immediately since this program is not currently accepting applications.
NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for sickle cell disease patients is currently closed and not accepting new applications. This program helps patients pay for medications and treatment costs related to sickle cell disease. You can check the PAN Foundation website to find out when the program reopens or to explore other assistance options.
WHY IT MATTERSIf you have sickle cell disease and were counting on PAN Foundation's copay assistance, you'll need to find alternative financial support resources immediately, as this major assistance program is not currently accepting applications.
NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition where the body can't break down a protein called phenylalanine — is currently closed. This program normally helps patients pay for treatment costs. The fund status changed on April 20, 2026.
WHY IT MATTERSIf you have PKU and were relying on PAN Foundation assistance to afford your medical care or special diet, you need to find alternative financial resources immediately since this program is no longer accepting applications.
NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for people with Spinal Muscular Atrophy (SMA) is currently closed and not accepting new applications. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them. You can check the program website to see when it reopens or find other financial help options.
WHY IT MATTERSIf you have SMA and struggle to afford your treatment, knowing this fund is temporarily closed helps you explore alternative financial assistance programs before your medication runs out.
NewsUNITERAREApr 20
The PAN Foundation's financial assistance program for Gaucher disease patients is currently closed and not accepting new applications. Gaucher disease is a genetic condition where the body can't break down certain fatty substances, causing organ damage. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them otherwise.
WHY IT MATTERSIf you have Gaucher disease and need help paying for your treatment, you'll need to find alternative financial assistance programs since this major funding source is temporarily unavailable.